Sektory a témata
Genomics and Personalised Medicine: Opportunity or Speculation?
Key takeaways
- Genomics covers DNA sequencing, gene therapies, diagnostics and CRISPR — it is a heterogeneous sector with varying degrees of maturity.
- Thematic ETFs on genomics concentrate risk: if the technology slows, the entire fund suffers.
- Clinical development stages for drugs take years; most companies are loss-making until a drug receives approval.
- Add thematic bets carefully — their share of the portfolio should not grow beyond the level of loss you can genuinely accept.
- The ETF route spreads the risk of individual company failures better than buying a single biotech stock.
Genomics and personalised medicine are areas of biotechnology where scientific progress is most rapidly translating into clinical practice — and where investment risks are among the highest in the technology world.
What the sector covers
Genomics is not one product — it is an ecosystem:
- Genome sequencing: technology that reads a patient's entire DNA quickly and cheaply
- Gene therapies: treating diseases by directly editing the genetic code
- CRISPR and gene editing: precision "scissors" for DNA, currently mainly in research
- Diagnostics: tests that detect disease before it manifests
- Personalised oncology: cancer treatment tailored to a tumour's genetic profile
How to invest in the sector
The most direct route is a thematic ETF tracking a genomics or biotech index. These typically include dozens of companies — from established pharmaceutical giants to small clinical-stage firms. An ETF diversifies against the risk of a single company's failure, but does not protect against the collapse of the entire thematic narrative. Before buying, check the fund's TER and its methodology (pure-play genomics firms, or a mix with pharma?). More on ETF selection can be found in the ETF Navigator.
Risks that cannot be ignored
Regulatory approval is slow and unpredictable — a failed clinical study can wipe out a large portion of a company's market value overnight. The sector performs differently in different interest-rate environments: when rates are higher, loss-making growth companies are hit harder. And finally, scientific promise and investment performance are not the same thing — a great technology does not necessarily mean strong returns within a given time window.
Where genomics fits in a portfolio
Thematic bets are seasoning, not the base. Genomics belongs in the portion of a portfolio allocated to higher risk. How large a share thematic bets should represent is discussed in a separate article. The foundation remains a global equity index.
FAQ
How do beginners invest in genomics?
The simplest route is a thematic ETF tracking genomic or biotech companies. It provides diversification and eliminates the risk of a single company's collapse — while retaining the sectoral risk of the entire industry.
Is genomics a safe investment?
No, it is among the riskier thematic bets. Companies are often loss-making, awaiting regulatory approval, and a single failed trial can cause a dramatic drop. It belongs only in the part of the portfolio reserved for higher risk.
What is CRISPR and why do investors talk about it?
CRISPR is a technology for precise DNA editing — in essence, genetic scissors. It holds the promise of treating hereditary diseases and cancer. Commercial applications are still in their early stages, however, and the road to regulatory approval takes years.